Literature DB >> 9592082

Mitogen-activated protein kinases (Erk1,2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M.

N D Amin, N G Ahn, H Jaffe, C A Winters, P Grant, H C Pant.   

Abstract

Mammalian neurofilament proteins, particularly midsized (NF-M) and heavy (NF-H) molecular weight neurofilament proteins, are highly phosphorylated in axons. Neurofilament function depends on the state of phosphorylation of the numerous serine/threonine residues in these proteins. Most phosphorylation occurs in the lys-ser-pro (KSP) repeats in the C-terminal tail domains of NF-H and NF-M. In our previous study, cyclin-dependent kinase 5 (cdk5) was shown to phosphorylate specifically the KSPXK repeats in rat NF-H. Because 80% of the repeats are of the KSPXXXK type, it was of interest to determine which kinase phosphorylates these motifs. Using a synthetic KSPXXXK peptide to screen for a specific kinase, we fractionated rat brain extracts by column chromatography and identified extracellular signal-regulated kinase (Erk2) activated by an upstream activator, the mitogen-activated protein kinase kinase MAPKK (MEK), by Western blot analysis, sequence identification, and inhibition by a specific MEK inhibitor (PD 98059). The fraction containing Erk2, as well as bacterially expressed Erk1 and Erk2, phosphorylated all types of KSP motifs in peptides (KSPXK, KSPXXK, KSPXXXK, and KSPXXXXK) derived from NF-M and NF-H. They also phosphorylated an expressed 24 KSPXXXK repeat NF-H polypeptide, an expressed NF-H as well as dephosphorylated native rat NF-H, and NF-M proteins with accompanying decreases in their respective electrophoretic mobilities. A comparative kinetic study of Erk2 and cdk5 phosphorylation of KSPXK and KSPXXXK peptides revealed that, in contrast to cdk5, which phosphorylated only the KSPXK peptide, Erk2 could phosphorylate both. The preferred substrate for Erk2 was KSPXXXK peptide. The MEK inhibitor PD 98059 also inhibited phosphorylation of NF-H, NF-M, and microtubule-associated protein (MAP) in primary rat hippocampal cells and caused a decrease in neurite outgrowth, suggesting that Erk1,2 may play an important role in neurite growth and branching. These data suggest that neuronal Erk1 and Erk2 are capable of phosphorylating serine residues in diverse KSP repeat motifs in NF-M and NF-H.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592082      PMCID: PMC6792805     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  85 in total

Review 1.  Dynamics of neuronal intermediate filaments: a developmental perspective.

Authors:  R A Nixon; T B Shea
Journal:  Cell Motil Cytoskeleton       Date:  1992

2.  Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (cdk5).

Authors:  A C Pant; H C Pant; N Amin
Journal:  Brain Res       Date:  1997-08-15       Impact factor: 3.252

3.  An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide.

Authors:  K H Jones; J A Senft
Journal:  J Histochem Cytochem       Date:  1985-01       Impact factor: 2.479

4.  Biochemical and immunocytochemical characterization and distribution of phosphorylated and nonphosphorylated subunits of neurofilaments in squid giant axon and stellate ganglion.

Authors:  R S Cohen; H C Pant; S House; H Gainer
Journal:  J Neurosci       Date:  1987-07       Impact factor: 6.167

5.  Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor.

Authors:  L Pang; T Sawada; S J Decker; A R Saltiel
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

6.  Dephosphorylation-induced interactions of neurofilaments with microtubules.

Authors:  S Hisanaga; N Hirokawa
Journal:  J Biol Chem       Date:  1990-12-15       Impact factor: 5.157

7.  Posttranslational modification of neurofilament polypeptides in rabbit retina.

Authors:  M A Glicksman; D Soppet; M B Willard
Journal:  J Neurobiol       Date:  1987-03

8.  Association of cyclic-AMP-dependent protein kinase with neurofilaments.

Authors:  A Dosemeci; H C Pant
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

9.  MAP kinase activator from insulin-stimulated skeletal muscle is a protein threonine/tyrosine kinase.

Authors:  S Nakielny; P Cohen; J Wu; T Sturgill
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

10.  Cross-linker system between neurofilaments, microtubules, and membranous organelles in frog axons revealed by the quick-freeze, deep-etching method.

Authors:  N Hirokawa
Journal:  J Cell Biol       Date:  1982-07       Impact factor: 10.539

View more
  61 in total

1.  Integrin alpha(1) beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation.

Authors:  B S Li; L Zhang; J Gu; N D Amin; H C Pant
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  NF-M is an essential target for the myelin-directed "outside-in" signaling cascade that mediates radial axonal growth.

Authors:  Michael L Garcia; Christian S Lobsiger; Sameer B Shah; Tom J Deerinck; John Crum; Darren Young; Christopher M Ward; Thomas O Crawford; Takahiro Gotow; Yasuo Uchiyama; Mark H Ellisman; Nigel A Calcutt; Don W Cleveland
Journal:  J Cell Biol       Date:  2003-12-08       Impact factor: 10.539

3.  A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Authors:  Ya-Li Zheng; Niranjana D Amin; Ya-Fang Hu; Parvathi Rudrabhatla; Varsha Shukla; Jyotshnabala Kanungo; Sashi Kesavapany; Philip Grant; Wayne Albers; Harish C Pant
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

4.  Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.

Authors:  Natalie Vavlitou; Irene Sargiannidou; Kyriaki Markoullis; Kyriacos Kyriacou; Steven S Scherer; Kleopas A Kleopa
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

5.  TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity.

Authors:  B K Binukumar; Ya-Li Zheng; Varsha Shukla; Niranjana D Amin; Philip Grant; Harish C Pant
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 6.  Defective neurofilament transport in mouse models of amyotrophic lateral sclerosis: a review.

Authors:  Mala V Rao; Ralph A Nixon
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

7.  The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins.

Authors:  Jyotshnabala Kanungo; Ya-Li Zheng; Niranjana D Amin; Harish C Pant
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

8.  Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease.

Authors:  Takahide Kaji; Barry Boland; Tatjana Odrljin; Panaiyur Mohan; Balapal S Basavarajappa; Corrinne Peterhoff; Anne Cataldo; Anna Rudnicki; Niranjana Amin; Bing Sheng Li; Harish C Pant; Basalingappa L Hungund; Ottavio Arancio; Ralph A Nixon
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Cyclin-dependent kinase 5 phosphorylation of human septin SEPT5 (hCDCrel-1) modulates exocytosis.

Authors:  Niranjana D Amin; Ya-Li Zheng; Sashi Kesavapany; Jyotshnabala Kanungo; Tad Guszczynski; Ram K Sihag; Parvathi Rudrabhatla; Wayne Albers; Philip Grant; Harish C Pant
Journal:  J Neurosci       Date:  2008-04-02       Impact factor: 6.167

10.  Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations.

Authors:  Ingrid K Svenson; Mark T Kloos; P Craig Gaskell; Martha A Nance; James Y Garbern; Shin-ichi Hisanaga; Margaret A Pericak-Vance; Allison E Ashley-Koch; Douglas A Marchuk
Journal:  Neurogenetics       Date:  2004-07-10       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.